Blau syndrome

Blau syndrome is an inflammatory disorder that primarily affects the skin, joints, and eyes. Signs and symptoms begin in childhood, usually before age 4.

A form of skin inflammation called granulomatous dermatitis is typically the earliest sign of Blau syndrome. This skin condition causes a persistent rash that can be scaly or involve hard lumps (nodules) that can be felt under the skin. The rash is usually found on the torso, arms, and legs.

Arthritis is another common feature of Blau syndrome. In affected individuals, arthritis is characterized by inflammation of the lining of joints (the synovium). This inflammation, known as synovitis, is associated with swelling and joint pain. Synovitis usually begins in the joints of the hands, feet, wrists, and ankles. As the condition worsens, it can restrict movement by decreasing the range of motion in many joints.

Most people with Blau syndrome also develop uveitis, which is swelling and inflammation of the middle layer of the eye (the uvea). The uvea includes the colored portion of the eye (the iris) and related tissues that underlie the white part of the eye (the sclera). Uveitis can cause eye irritation and pain, increased sensitivity to bright light (photophobia), and blurred vision. Other structures in the eye can also become inflamed, including the outermost protective layer of the eye (the conjunctiva), the tear glands, the specialized light-sensitive tissue that lines the back of the eye (the retina), and the nerve that carries information from the eye to the brain (the optic nerve). Inflammation of any of these structures can lead to severe vision impairment or blindness.

Less commonly, Blau syndrome can affect other parts of the body, including the liver, kidneys, brain, blood vessels, lungs, and heart. Inflammation involving these organs and tissues can cause life-threatening complications.

Frequency

Although Blau syndrome appears to be uncommon, its prevalence is unknown.

Genetic Changes

Blau syndrome results from mutations in the *NOD2* gene. The protein produced from this gene helps defend the body from foreign invaders, such as viruses and bacteria, by playing several essential roles in the immune response, including inflammatory reactions. An inflammatory reaction occurs when the immune system sends signaling molecules and white blood cells to a site of injury or disease to fight microbial invaders and facilitate tissue repair.

The *NOD2* gene mutations that cause Blau syndrome result in a NOD2 protein that is overactive, which can trigger an abnormal inflammatory reaction. However, it is unclear how overactivation of the NOD2 protein causes the specific pattern of inflammation affecting the joints, eyes, and skin that is characteristic of Blau syndrome.

Inheritance Pattern

Blau syndrome is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. Most affected individuals have one parent with the condition.

In some cases, people with the characteristic features of Blau syndrome do not have a family history of the condition. Some researchers believe that these individuals have a non-inherited version of the disorder called early-onset sarcoidosis.

Other Names for This Condition

- arthrocutaneouveal granulomatosis
- early-onset sarcoidosis
- familial granulomatosis, Blau type
- familial juvenile systemic granulomatosis
- granulomatous inflammatory arthritis, dermatitis, and uveitis, familial
- pediatric granulomatous arthritis

Diagnosis & Management

These resources address the diagnosis or management of Blau syndrome:

- Genetic Testing Registry: Blau syndrome https://www.ncbi.nlm.nih.gov/gtr/conditions/C1861303/
- Genetic Testing Registry: Sarcoidosis, early-onset https://www.ncbi.nlm.nih.gov/gtr/conditions/C1836122/
- Merck Manual Consumer Version: Overview of Dermatitis
 http://www.merckmanuals.com/home/skin-disorders/itching-and-dermatitis/
 overview-of-dermatitis
- Merck Manual Consumer Version: Uveitis
 http://www.merckmanuals.com/home/eye-disorders/uveitis-and-related-disorders/uveitis

These resources from MedlinePlus offer information about the diagnosis and management of various health conditions:

- Diagnostic Tests https://medlineplus.gov/diagnostictests.html
- Drug Therapy https://medlineplus.gov/drugtherapy.html
- Surgery and Rehabilitation https://medlineplus.gov/surgeryandrehabilitation.html
- Genetic Counseling https://medlineplus.gov/geneticcounseling.html
- Palliative Care https://medlineplus.gov/palliativecare.html

Additional Information & Resources

MedlinePlus

- Encyclopedia: Synovial Fluid https://medlineplus.gov/ency/imagepages/19698.htm
- Encyclopedia: The Uvea https://medlineplus.gov/ency/article/002337.htm
- Encyclopedia: Uveitis https://medlineplus.gov/ency/article/001005.htm
- Health Topic: Arthritis
 https://medlineplus.gov/arthritis.html
- Health Topic: Eye Diseases https://medlineplus.gov/eyediseases.html
- Health Topic: Skin Conditions https://medlineplus.gov/skinconditions.html

Genetic and Rare Diseases Information Center

 Blau syndrome https://rarediseases.info.nih.gov/diseases/304/blau-syndrome

Additional NIH Resources

- National Eye Institute: Uveitis https://nei.nih.gov/health/uveitis/uveitis
- National Institute of Arthritis and Musculoskeletal and Skin Diseases: Arthritis https://www.niams.nih.gov/Health_Info/Arthritis/

Educational Resources

- MalaCards: blau syndrome http://www.malacards.org/card/blau syndrome
- Merck Manual Consumer Version: Overview of Dermatitis
 http://www.merckmanuals.com/home/skin-disorders/itching-and-dermatitis/
 overview-of-dermatitis
- Merck Manual Consumer Version: Uveitis
 http://www.merckmanuals.com/home/eye-disorders/uveitis-and-related-disorders/uveitis
- Orphanet: Blau syndrome http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=90340

Patient Support and Advocacy Resources

- Autoinflammatory Alliance http://autoinflammatory.org/blau.php
- Ocular Immunology and Uveitis Foundation http://www.uveitis.org/

Genetic Testing Registry

- Blau syndrome https://www.ncbi.nlm.nih.gov/gtr/conditions/C1861303/
- Sarcoidosis, early-onset https://www.ncbi.nlm.nih.gov/gtr/conditions/C1836122/

Scientific Articles on PubMed

 PubMed https://www.ncbi.nlm.nih.gov/pubmed?term=%28blau+syndrome%5BTIAB%5D%2 9+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+1800+days %22%5Bdp%5D

OMIM

 BLAU SYNDROME http://omim.org/entry/186580

Sources for This Summary

- Borzutzky A, Fried A, Chou J, Bonilla FA, Kim S, Dedeoglu F. NOD2-associated diseases: Bridging innate immunity and autoinflammation. Clin Immunol. 2010 Mar;134(3):251-61. doi: 10.1016/j.clim.2009.05.005. Epub 2009 May 24. Review.
 Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19467619
- Kanazawa N, Okafuji I, Kambe N, Nishikomori R, Nakata-Hizume M, Nagai S, Fuji A, Yuasa T, Manki A, Sakurai Y, Nakajima M, Kobayashi H, Fujiwara I, Tsutsumi H, Utani A, Nishigori C, Heike T, Nakahata T, Miyachi Y. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood. 2005 Feb 1;105(3): 1195-7. Epub 2004 Sep 30.
 Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15459013
- Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Häfner R, Chamaillard M, Zouali H, Thomas G, Hugot JP. CARD15 mutations in Blau syndrome. Nat Genet. 2001 Sep;29(1): 19-20.
 - Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11528384
- Punzi L, Furlan A, Podswiadek M, Gava A, Valente M, De Marchi M, Peserico A. Clinical and genetic aspects of Blau syndrome: a 25-year follow-up of one family and a literature review. Autoimmun Rev. 2009 Jan;8(3):228-32. doi: 10.1016/j.autrev.2008.07.034. Epub 2008 Aug 19. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18718560
- Punzi L, Gava A, Galozzi P, Sfriso P. Miscellaneous non-inflammatory musculoskeletal conditions. Blau syndrome. Best Pract Res Clin Rheumatol. 2011 Oct;25(5):703-14. doi: 10.1016/j.berh.2011.10.017. Review.
 Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22142748
- Rose CD, Martin TM, Wouters CH. Blau syndrome revisited. Curr Opin Rheumatol. 2011 Sep;23(5): 411-8. doi: 10.1097/BOR.0b013e328349c430. Review.
 Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21788900
- Rosé CD, Aróstegui JI, Martin TM, Espada G, Scalzi L, Yagüe J, Rosenbaum JT, Modesto C, Cristina Arnal M, Merino R, García-Consuegra J, Carballo Silva MA, Wouters CH. NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a national cohort in Spain. Arthritis Rheum. 2009 Jun;60(6):1797-803. doi: 10.1002/art.24533. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19479837
 Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768567/
- Rosé CD, Doyle TM, McIlvain-Simpson G, Coffman JE, Rosenbaum JT, Davey MP, Martin TM. Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis. J Rheumatol. 2005 Feb;32(2):373-5.
 Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15693102
- Wang X, Kuivaniemi H, Bonavita G, Mutkus L, Mau U, Blau E, Inohara N, Nunez G, Tromp G, Williams CJ. CARD15 mutations in familial granulomatosis syndromes: a study of the original Blau syndrome kindred and other families with large-vessel arteritis and cranial neuropathy. Arthritis Rheum. 2002 Nov;46(11):3041-5.
 Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12428248

Reprinted from Genetics Home Reference:

https://ghr.nlm.nih.gov/condition/blau-syndrome

Reviewed: July 2012

Published: February 14, 2017

Lister Hill National Center for Biomedical Communications U.S. National Library of Medicine National Institutes of Health Department of Health & Human Services